Shenzhen Haplox Biotechnology Co., Ltd. is a hi-tech enterprise whom devoted itself into R&D and clinical application in ultromicro tumor genetic inspection,

China’s National Health and Family Planning Commission announced the final list of the first series of the national health insurance negotiation, while the oral targeted drug Erlotinib (Tarceva),

Recently, WuXi App Tec as well as WuXi NextCode, and Huawei jointly issued China's first Precision Medical Cloud platform in Shanghai.

On June 3rd, the big data company for tumor, Sipai Network announced that it has already finished tens of millions of dollars for B round financing in this week from Tencent Venture,

According to the CEO of Novartis, Joe Jimenez, Novartis may exit from the board of Roche without the premium, as long as the situation is allowed.

Illumina has sued Qiagen, alleging that the company's GeneReader next-generation sequencing instrument infringes on a patent Illumina holds related to sequencing

Under the banner of Greenery Group, Vela Diagnostics announced recently that, it is going to acquire the data analysis business of the cancer molecular diagnostic company lifecode,

Recently, Ningbo Medicalsystem Biotechnology Co., Ltd.’s wholly owned subsidiary - NINGBO ALABAMA,LLC acquiring U.S.

The company, which launched last year with an initial $100 million in investments from Illumina, Warburg Pincus, and Sutter Hill Ventures, plans to launch its first product in the fourth quarter of this year.

The French government announced that it plans to invest €670 million ($760.8 million) in a genomics and personalized medicine program meant to improve the diagnosis and prevention of disease in the country.

Recently, assist cancer detection company Vigilant Biosciences announced that it got another 5 million dollars of B round financing, invested by White Owl Capital Partners and venVelo.

Recently£¬US seed company Monsanto refused Germany Bayer’s takeover bid that up to 65 billion dollars. But at the same time, it also said it would keep an open attitude to negotiate with Bayer and other bidders.

Recently£¬Bio-Techne announced that it has agreed to acquire Advanced Cell Diagnostics for $250 million in cash, plus an additional consideration of $75 million if certain milestones are achieved.

Recently, the medical equipment company NVision Medical announced the accomplishment of its B round financing, which has raised 12 million USD,leading by Arboretum Ventures, and followed by Catalyst Health Ventures.

Under the present medical system, the influence of human genome is very limited, because of some basic challenges: the providers cannot receive the related resources in time,